share_log

港股异动 | 君实生物(01877)拉升逾8% VV116产业化项目获备案 拟筹近40亿用于创新药研发

Hong Kong stock changes | Junshi Bio (01877) pulls up more than 8% VV116 industrialization project to be put on record and plans to raise nearly 4 billion for innovative drug research and development.

Zhitong Finance ·  Jun 17, 2022 13:40

Zhitong Financial APP learned that Junshi Bio (01877) rose more than 8% in the afternoon and rose 8.33% to HK $43.55 as of press time, with a turnover of HK $76.897 million.

According to the news, according to the Securities Times, the online examination and approval supervision platform for investment projects in Shanghai shows that recently, the filing of Junshi's VV116 (deuterium hydrobromide Remidvir tablets) industrialization project was approved by the management committee of Zhangjiang High-tech Park.

In addition, Junshi announced that it is proposed to issue up to 70 million A shares, and the total proceeds are expected to be adjusted from the original 3.98 billion yuan to 3.969 billion yuan, of which about 3.671 billion yuan will be used for innovative drug research and development projects. about 298 million yuan will be used for the Shanghai Junshi Biotechnology headquarters and R & D base project.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment